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E-mail address: lyoung@rcsi.ie (L.S. Young).Human cancers utilise telomerase to maintain telomeres and prohibit cell senescence. Human tel-
omerase reverse transcriptase (hTERT), an essential component of this complex, is regulated at
the level of gene transcription. Using SILAC-proteomic analysis and molecular studies, we identiﬁed
the AAA+ ATPase, RuvBl2 as a transcriptional regulator of hTERT and established that this regulation
is through cooperation with Ets-2. In colon cancer patients, nuclear expression of RuvBl2 associated
with nuclear expression of hTERT, pEts2 and advanced nodal disease (P < 0.01, P = 0.05 and P = 0.03
respectively, n = 170). These data ﬁrmly implicate RuvBl2 in Ets2 mediated regulation of hTERT in
colon cancer which has functional and clinical consequences.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Telomerase, the nucleoprotein reverse transcriptase which
compensates for loss of telomere sequence, is ordinarily conﬁned
to germinal and adult stem cells [1]. Cellular immortality by means
of telomeremaintenance is regarded as one of the six characteristics
that deﬁne a tumour cell [2]. The majority (85–90%) of malignant
cancers, including those of the colon, are known to express telome-
rase activity for this purpose with the remainder maintaining their
telomeres by employing a recombination-based mechanism
referred to as alternative lengthening of telomeres (ALT) [3,4].
Telomerase and its associated regulators are therefore considered
potential therapeutic anticancer targets.
Telomerase undergoes a complex macromolecular assembly
process, but in its active form is known to consist of at least three
components: human telomerase (hTR), human telomerase enzyme
reverse transcriptase (hTERT) and dyskerin [5,6]. Regulation of
telomerase, though not yet fully understood is thought to occur
throughmultiplemechanisms. Access of the active telomerase com-
plex to its substrate is inhibitedbyvarious shelterin components [7].
Other components of telomerase are ubiquitously expressed andchemical Societies. Published by E
ogy Research, Department of
ouse, York Street, Dublin 2,overall regulation is therefore largely dependent on hTERT gene
expression. The epigenetic status of the hTERT gene promoter is a
signiﬁcant determinant governing its expression with histone acet-
ylationandDNAhypomethylation in the vicinity of the transcription
start site serving as two key hallmarks that denote a transcription-
ally active hTERT gene [8–10].
Transcriptional repression of the hTERTgene is inducedby a vari-
ety of transcription factors (TFs), including tumour suppressors such
as p53 and BRCA1 [11–15]. Similarly, a large number of TFs are
known to activate hTERT transcription such as Sp1, c-Myc, GRHL2
and AP2 [16–22]. Of these, c-Myc has been directly observed to
interact with E-boxes and its activation of hTERT transcription is
partly dependent on chromatin conﬁguration of the hTERT gene
[23,24]. More recently, in breast cancer cells, c-Myc regulation of
hTERT has been shown to be dependent on interactions with the
transcription factor Ets2 [22]. Ets proteins are a family of mitogen-
activated protein kinase (MAPK)-dependent transcription factors,
which have been implicated as downstream effectors of growth fac-
tor signaling [25]. They contain a conservedwingedhelix-turn-helix
DNA binding domain, regulating gene expression by binding to Ets
binding sequences found in promoter/enhancer regions of their
target genes. Full transcriptional activity of Ets proteins requires
interactions with co-activator/co-integrator proteins [9,26,27].
Elevatedexpression levels of Etsproteins are associatedwithdisease
progression in several tumours, including those of the colon [28,29].lsevier B.V. All rights reserved.
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conjunction with mass spectrometry analysis, enables a quantita-
tive comparison of the proteomes of two cell populations [30]. In
this study, we have used SILAC to compare the nuclear proteomes
of two genetically similar ﬁbroblast-derived cell lines which use
telomerase and ALT to maintain their telomeres. Our aim was to
identify new telomerease regulators. A number of differentially ex-
pressed proteins were identiﬁed which included the AAA+ ATPase,
RuvB-like helicase 2 (RuvBl2, RVB2, reptin, TIP48, ECP51, INO80 J,
TIH2, TIP49B). RuvBl2 along with its homologous partner RuvBl1
(pontin) interacts with both hTERT and dyskerin and are essential
for telomerase holoenzyme assembly [31]. Apart from its function
in chromatin remodelling, a direct role for RuvBl2 in hTERT regula-
tion has recently been described [32]. Here we investigated the
role of RuvBl2 in hTERT transcriptional activation and examined
the relationship between RuvBl2 and Ets2 in the regulation of
hTERT in colon cancer.2. Materials and methods
2.1. Cell lines, cell culture and treatments
The JFCF-1-3C (telomerase negative) and JFCF- 6G (telomerase
positive) cell lines were a kind gift from Professor Roger Reddel,
University of New South Wales, Australia. The cell lines were both
derived from JFCF6 jejunal ﬁbroblasts which had been immorta-
lised following transfection with SV40 ER. The SV40 ER transfected
JFCF6 clones that spontaneously escaped crisis were isolated and
determined to have either activated (6G) or maintained telomeres
(1-3C) via ALT. Cells were cultured in Dulbecco’s modiﬁed eagle’s
medium (D-MEM; Gibco, USA) supplemented with 10% dialysed fe-
tal bovine serum (FBS; Gibco, USA) and 0.1% gentamicin (Gibco,
USA). The HCA-7 cell line was obtained from the American Type
Culture Collection (ATCC) and was also cultured in DMEM supple-
mented with 10% FBS as were the SUSM-1 and GM369 telomerase
negative and telomerase positive cell lines. All cell lines were cul-
tured at 37 C and 5% CO2. For EGF stimulation cells were serum
starved in serum free DMEM for 24 h prior to treatment with
10 ng/ml EGF (Sigma).
2.2. Semi-quantitative PCR
Semi-quantitative real-time PCR (Lightcycler, Roche Laborato-
ries) was carried out to determine mRNA levels of RuvBl2, norma-
lised to beta-actin, in SUSM-1, 1-3C and 6G cell lines. 3  106 cells
were harvested and RNA extracted using RNeasy kit (Qiagen) as
per manufacturer’s protocol. Reverse transcription was carried out
using theMMLVRT enzyme (Invitrogen, USA) as permanufacturer’s
instructions and cDNA was ampliﬁed using QuantiTect SYBR Green
(Qiagen) with the following primers: RuvBl2 F: 50GCAAACTGACCCT
CAAGACC 30; RuvBl2 R: 50 GAGCCCATAGCGTCGTAGTC 30; B-actin F:
50TCACCCACACTGTGCCCATCTC 30 and B-actin R: 50TGGCAATGAGC
GGTTCCGCTG 30.
2.3. Western blot analysis
Nuclear and cytoplasmic lysateswere prepared using theNE-PER
Nuclear andCytoplasmic ExtractionReagents kit (PierceBiotechnol-
ogy, USA) andprotein concentrationswere assayedusing the BCAkit
(Pierce Biotechnology, USA). 30 lg of nuclear and cytoplamic pro-
tein or 30-150 lg of total cell lysate was loaded onto an SDS–PAGE
gel as previously described [33]. Antibodies were as follows: hTERT
1:500 (Abcam, ab5181), RuvBl2 1:500 (Abcam, 36569), Ets2 1:200
(Santa Cruz Biotechnology, sc-351), beta-actin 1:7500 (Sigma,
AI978).2.4. siRNA and plasmids
Predesigned small interfering RNAdirected against Ets2 (Invitro-
gen, cat.No. 46-1590), RuvBl2 (Ambion ID s21309) andanon-target-
ing siRNA (Ambion, AM4635) were used to knock down gene
expression. Transfection was carried out using the siPORT Lipid
reagent (Ambion) as per instructions. Cells were seeded in a 12-well
dish at 2  105 cells per well. Final concentrations for siRuvBl2 and
siEts2 were 10nM and 100nM respectively. The Ets-2 expression
vector (pCGN-Ets-2) and the empty control PCGN vector were a gift
from Dr Toshihiko Ezashi, University of Missouri-Columbia, Colum-
bia, MO, USA [34]. 24 h prior to transfection 5  105 HCA7 cells per
wellwere seeded into a 6well dish, 4 lg pCGN-Ets-2 and pCGN con-
trol vector were transfected using lipofectamine 2000 (Invitrogen)
as per manufacturer’s instructions. Whole cell lysate was harvested
24 h post transfection and analyzed on an SDS–PAGE gel.
2.5. ChIP analysis
Chromatin immunoprecipitation was performed as previously
described [35]. The supernatant fraction of 6G cells were incubated
with anti-RuvBl2 (7 lg), anti-Myc (Santa Cruz) (7 lg) or H4 anti-
body (Upstate) (7 lg). Primers used to amplify the hTERT promoter
were: F: 50GGCCGATTCGACCTCTCT 30 and R: 50CGGAGCTGGAAGG-
TGAAG 30.
2.6. Dual-luciferase reporter assay
A renilla-luciferase reporter assay was carried out to examine
the effect of Ets2/c-Myc and RuvBl2 on hTERT promoter activity.
The pLUC-330/pGL2-enhancer vector containing a 330 bp insert
of the hTERT promoter was kindly provided by Silvia Bacchetti
(McMaster University, Ontario) and has been previously described
[36]. A total of 5  104 cells were seeded on a 24-well plate in anti-
biotic free media for 24 h. Cells were transfected with 50 ng Renilla
vector (as an internal transfection control), 5 lg pLuc330/pLuc and
0.1 nM scrambled, RuvBl2, c-Myc or Ets2 siRNA using Lipofect-
amine 2000 reagent (Invitrogen) as per manufacturer’s instruc-
tions. 24 h after transfection cells were harvested and luciferase
activity was tested using the Dual-Luciferase Reporter Assay Sys-
tem (Promega) as instructed by the manufacturer and luciferase
detection was measured on Junior LB Luminometer (Berthold
Technologies, Bad Wildbad, Germany). Experiments were carried
out in duplicate in 3 independent experiments.
2.7. Telomerase repeat ampliﬁcation protocol (TRAP)
The TRAP assay (Roche Diagnostics, Germany) was carried out
to assess telomerase activity as per manufacturer’s instructions.
Brieﬂy, cells were transfected with siRNA constructs and whole cell
lysate harvested. Lysate was added to a reaction mix containing
biotin-labelled primers P1-Ts and P2. Telomerase adds telomeric re-
peats to the P1–Ts primers and PCR is carried out to amplify the
product. The amplicon was denatured and hybridized to a detec-
tion probe labelled with the antibody digoxigenin; the product is
immobilized to a steptavidin microplate and incubated with
anti-digoxigenin conjugated to HRP. Substrate TMP (3,30,5,50-
tetramethylbenzedrine) is added and colour change was detected
by absorbance using a microplate reader (Biotek, USA). Telomerase
activity was determined by subtracting absorbance A690nm from
A450nm for each sample.
2.8. Immunohistochemistry
Following ethical approval, archival parafﬁn-embedded colon
tumour sections were obtained from the Department of Pathology,
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histochemistry was performed using the Vecta Stain Elite kit pro-
tocol. Sections were incubated with anti-RuvBl2, anti-hTERT and
anti-pEts2 [pT72] (Invitrogen, cat no. 44-1105G), at 1:400, 1:100
and 1:500 dilutions respectively. Sections were stained with DAB
3,30-diaminobenzidine (Sigma) and counter stained with haema-
toxylin for nuclear detection. Slides were examined under the
microscope. Staining was scored using a modiﬁed version of the
Allred scoring system as previously described [37].
2.9. Mass spectrometry assay by SILAC
Stable-isotope labelling by amino acids in cell culture was used
for relative quantitation of the nuclear proteome in 6G and 1-3C
cell lines. Telomerase-negative, 1-3C ﬁbroblasts were grown in
minimal medium without arginine and lysine and were supple-
mented with 14N4, 12C6-Arg and 12C6-lysine. The 6G telomerase-po-
sitive ﬁbroblasts were grown in minimal media without regular
arginine and lysine and were supplemented with the respective
isotopes, 15N4, 13C6-Arg and 13C6 lysine. Cells were harvested and
lysed. Nuclear protein extracts were combined and resolved by
SDS–PAGE. Peptides were analysed by LC–MS/MS on a Bruker
HCT Ultra ion-trap system. To conﬁne data acquisition to highly
differentially expressed proteins that were more likely to be of
interest, the ‘stable isotope labelling experiment’ (SILE) parameter
was applied during the data acquisition phase for the selective
acquirement of data between 2 speciﬁcally set intensity ratio val-
ues. The corresponding .mgf ﬁles were then searched using the
X!Tandem search algorithm against the human SWISS-PROT pro-
tein database. Proteins identiﬁed via this search were checked for
peptides which had E-values that did not exceed -3. MS spectra
were then examined to identify the corresponding peak doublets
and determine the (heavy/low) peptide ratio.
3. Results and discussion
3.1. Identiﬁcation and conﬁrmation of RuvBl2 as a regulator of hTERT
To isolate proteins implicated in the regulation of telomerase,
isogenic cell lines, JFCF-6G (6G) and JFCF-1-3C (1-3C) were used
which were telomerase-positive and telomerase-negative, respec-
tively [38]. To maintain their telomeres in the absence of telome-
rase, cells utilise the ALT mechanism of which a standard
characteristic is the presence of relatively heterogeneous telomere
lengths [39,40]. A telomere repeat fragment length analysis dem-
onstrated that telomeres of the telomerase-negative 1-3C cell lineTable 1
Relative quantitation of the nuclear proteome in 6G and 1-3C cell lines
Protein Uniprot Acc
RuvBl2 Q9Y230
hnRNP A1 P09651
HSP-related protein 70kD protein2 P54652
hnRNP A1-like protein 2 Q32P51
hnRNP A2/B1 P22626
Myosin-11 P35749
Peripherin P41219
Actin-like protein 3 P61158
Ubiquitin-conjugating enzyme E2 N P61088
Mitochondrial import inner membrane translocase subunit TIM13B Q9Y5L4
GTFII-I P78347
60S ribosomal protein L11 P62913
G-protein-signalling modulator 1 Q86YR5
Phosphatidylethanolamine-bindingprotein 1 P30086
Myosin-1a Q9UBC5
Signal transducer and activator oftranscription 1 P42224
Tubulin-alpha 1 B chain P68363
Succinate dehydrogenase P21912exhibit this characteristic in contrast to the 6G cell line (Supple-
mental Figure A) suggesting that the former utilises ALT as a telo-
mere maintenance mechanism. Both of these cell lines therefore
provide an ideal experimental background for isolating regulators
of the telomerase activation pathway.
SILAC labelling combined with LCMS was used to compare the
proteomes of both of these cell lines. This technique involves cul-
turing both cell types in minimal media that either contain heavy
versions of the amino acids L-Arg [13C6] and L-Lys [13C6] [30] or
light versions of these amino acids. The 1-3C cells were metaboli-
cally labelled with ‘light’ [12C, 14N] L-arginine and L-lysine whereas
the 6G cells were grown in medium containing ‘heavy’ [13C6]
L-arginine and L-lysine. Equal amounts of nuclear extract from
each cell line were harvested, pooled and resolved by SDS–poly-
acrylamide gel electrophoresis (PAGE) (Supplemental Figure B).
Sections of the gel were then excised, subjected to in-gel digestion
with trypsin and analysis by LCMSMS. The relative expression level
of a number of peptides was then obtained by manual integration
of the peptide pseudomolecular ions (Table 1). A number of pro-
teins were found to be differentially expressed such as Signal
Transducer and Activator of Transcription 1 (STAT1), Ubiquitin
E2 N ligase (UBE2 N). RuvB-like helicase 2 was upregulated in the
telomerase-positive 6G cell line (Fig. 1A and Supplemental Figure
C). RuvBl2 is a homohexameric complex that belongs to the AAA+
(ATPases associated with diverse cellular activities) family of ATP-
ases and performs a number of functions in the control of gene
expression, aspects of DNA repair and snoRNP assembly [41]. In
particular, RuvBl2 has been identiﬁed as a component of the inac-
tive telomerase complex [31]. We therefore decided to explore the
possibility that RuvBl2 also modulates hTERT gene expression to
control telomerase activity.
No alteration in the transcript levels of RuvBl2 was observed in
the hTERT positive (6G) cells in relation to the hTERT negative (1-
3C) cells (Fig. 1B). In conﬁrmation of the SILAC proteomic studies,
enhanced RuvBl2 protein was however detected in the nuclear
fraction of the 6G cells in comparison to the 1-3C cells (Fig. 1C).
Of all telomerase components, the hTERT catalytic subunit is con-
sidered to be the rate-limiting component and its activity is mainly
controlled at the transcriptional level [42]. Given that RuvBl2 has
also been implicated in telomerase assembly, we therefore hypoth-
esised that RuvBl2 might inﬂuence telomerase activity through the
additional means of hTERT transcriptional control. We examined
RuvBl2 recruitment to the hTERT promoter using primers that
encompassed the proximal E-box as RuvBl2 has been shown to reg-
ulate transcription in a manner dependent on the c-Myc transcrip-
tion factor [43]. RuvBL2 was present at the hTERT promoter under. code Mr No. of peptides Log(e) Band no. 6G: 1-3C
51.1 1 7.6 29 3.9
38.6 3 3.2 23 4.8
70 3 3.6 17 6.4
34.2 2 3.5 23 5.8
37.4 1 2.9 24 2.7
227.3 1 6.8 9 1.1
53.7 1 3.6 11 1.3
47.4 1 13 1.1
17.1 28 1.1
10.5 1 5.7 25 2.8
112.4 1 5.2 12 4.2
20.3 1 5.0 26 2.9
72.1 1 4.4 3 1.9
21 1 4.1 26 1.3
118.4 1 4.1 13 3.3
87.3 1 3.8 16 4.4
50.2 1 3.7 29 1.7
31.6 1 3.1 17 7.4
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Fig. 1. Identiﬁcation and conﬁrmation of RuvBl2 as a regulator of hTERT. (A) Using SILAC, RuvB-like helicase 2 (RuvBl2) was identiﬁed as a potential regulator of hTERT, being
up-regulated in the 6G cell line when compared with the 1-3C cell line. The spectrum for the peptide is shown together with the amino acid sequence which matched
uniquely to the RuvBl2 protein sequence. (B) Transcript levels of RuvBl2 were determined with quantitative real-time PCR in SUSM-1 cells (telomerase negative control), 1-3C
(telomerase negative) cells and 6G (telomerase positive) cells. (C) Enhanced Ruvbl2 protein expression is detected in the nuclear fraction of 6G cells in comparison to 1-3C
cells. Cytoplasmic (c) and nuclear (n) protein levels of RuvBl2 in 1-3C, 6G, SUSM-1 and GM639 (telomerase positive control) cells were examined by western blot. Actin was
used as a loading control. Blot shown is representative of three separate experiments. Densitometric analysis of western blots conﬁrms strong nuclear expression of RuvBl2 in
6G cells. (D) Cartoon of the hTERT promoter with the Myc binding site (E-box) and proposed recruitment of RuvBl2 with EGF treatment illustrated. RuvBl2 binds to the hTERT
promoter under EGF treatment by ChIP. After immunoprecipitation with rabbit anti-RuvBl2, rabbit anti-Myc or H4 antibody, primers were used to amplify the DNA 366 to
142 of the hTERT transcriptional start site. Genomic DNA, no template control, no antibody and H4 control samples are shown. PCR image is representative of four separate
experiments. Bar chart shows densitometry analysis of results. (E) The effect of knock-down RuvBl2 expression on hTERT promoter activity relative to Myc knockdown in 6G
cells (i) and colon cancer HCA-7 cells (ii). RuvBl2 and Myc expression were knocked down by siRNA (Ambion). The pLuc-330 construct was a pGL2 enhancer plasmid that
harbours 330 bp of the core hTERT promoter linked to a ﬁreﬂy luciferase construct. Luciferase assays were carried out using a Dual-Glo luciferase assay system, luciferase
reporter activity was normalised to Renilla luciferase, results are expressed as mean ± SD (n = 3). (F) RuvBl2 expression was knocked down by siRNA in 6G cells and western
blotting was carried out to determine effect on RuvBL2 and hTERT protein levels. Actin was used as a loading control. Blot shown is representative of three separate
experiments.
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Fig. 2. RuvBl2 can cooperate with Ets-2 to regulate hTERT. (A) Cartoon of the hTERT promoter with the Myc binding site (E-box) and the Ets binding site illustrated, along
with the proposed Ets2 binding on treatment with EGF. ChIP was performed on 6G cells treated with vehicle or EGF as described. Cell fractions were immunoprecipitated with
either rabbit anti-Ets2 (sc-351, Santa Cruz) or H4 antibody. Proteins were uncrosslinked and primers were used to amplify the DNA 366 to 142 of the hTERT transcriptional
start site. PCR image is representative of four separate experiments. (B) The effect of knock-down RuvBl2 expression on hTERT promoter activity relative to Ets2 knockdowns
in 6G cells (i) colon cancer HCA-7 cells (ii). Luciferase assays were carried out using a Dual-Glo luciferase assay system, luciferase reporter activity was normalised to Renilla
luciferase, results are expressed as mean ± SD (n = 3). (C) Knock down of RuvBl2 and Ets-2 expression with siRNA reduced hTERT protein expression in HCA-7 and 6G cells as
determined by western blot. Actin was used as a loading control. Blots shown are representative of three separate experiments. (D) Over-expression of Ets2 with pCGN Ets2
induced an increase in hTERT expression compared to empty vector control (pCGN). Concomitant knock down of RuvBl2 with siRNA inhibited Ets2 induced hTERT protein
expression as determined by western blot. Actin was used as a loading control. Blot shown is representative of three separate experiments. Conﬁrmation of successful
knockdown of RuvBl2 and over-expression of Ets2 in HCA-7 cells. Blots shown are representative of three separate experiments.
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AB
Fig. 3. RuvBl2 impacts hTERT activity and associates with pEts2 and hTERT
expression in human colon cancer patients. (A) Knock down of RuvBl2 or Ets2
induces a reduction in telomerase activity in 6G and HCA-7 colon cancer cells. TRAP
assay was used to assess telomerase activity. siRNA-mediated depletion of RuvBl2
or Ets2 signiﬁcantly reduced telomerase activity in 6G and HCA-7 cell lines
compared to respective controls (F-statistic = 2,146, P < 0.001). 1-3 cells where used
as hTERT negative control cells. Results are expressed as mean ± SD (n = 3). (B)
RuvBl2, pEts2 and hTERT (200 inset 600) were localised in tumour tissue from
colon cancer patients (n = 170). Staining was scored using the Allred scoring system
as previously described [37]. Signiﬁcant associations were observed between
nuclear expression of RuvBl2 and pEts2 (P = 0.05, Fisher’s exact test) and between
nuclear expression of RuvBl2 and hTERT (P = 0.004, Fisher’s exact test).
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treatment with the growth factor EGF (Fig. 1D). Using a modiﬁed
pGL2-enhancer construct which contains the 330 bp upstream of
the ﬁrst codon [36], we looked at the contribution of RuvBl2 to
the hTERT promoter activity. Knockdown of both RuvBl2 and c-
Myc signiﬁcantly reduced luciferase activity in both the 6G and
the HCA-7 colon cancer cells (Fig. 1E). Furthermore, RuvBl2 knock-
down resulted in reduction of hTERT protein expression (Fig. 1F).
These data indicate that RuvBl2 can be recruited to the hTERT
proximal promoter under the inﬂuence of the growth factor EGF,
and that RuvBl2 is essential for full transcriptional activation of
the hTERT gene.
3.2. RuvBl2 can cooperate with Ets-2 to regulate hTERT
Ets binding regions have been identiﬁed in the proximal pro-
moter of hTERT. Though there has been some controversy as to
whether Ets2 transcriptionally activates or represses the gene, re-
cent work by Xu et al suggests that Ets2 can positively regulate
hTERT by interacting with c-Myc [22]. In this study we observed
a growth factor dependent Ets2 recruitment to the same hTERT
promoter region as RuvBl2 (Fig. 2A, Supplemental Figure D). Fur-
thermore knockdown of RuvBl2 or Ets2 reduced hTERT promoter
activity and protein expression in 6G cells and HCA-7 colon cancer
cells (Fig. 2B and C). Ets2 requires interactions with coactivator/co-
integrator proteins, including p160s and CBP/p300 for full tran-
scriptional activity [9,26,27]. Apart from its role in telomerase
assembly [31], hTERT can also function as a transcriptional coacti-
vator [32,43]. In this study forced expression of Ets2 upregulated
hTERT protein expression in colon cancer cells, whereas concomi-
tant knockdown of RuvBl2 reduced Ets2 dependent hTERT regula-
tion (Fig. 2D). Taken together these data implicate RuvBl2 in the
control of Ets2 mediated hTERT expression.
3.3. RuvBl2 impacts hTERT activity and associates with hTERT
expression in human colon cancer patients
The ability of RuvBl2 and Ets2 to inﬂuence hTERT activity was
examined. Knockdown of the transcription factor and the putative
coactivator protein reduced hTERT activity in both the 6G and
HCA-7 cell lines as determined by a telomere repeat ampliﬁcation
(TRAP) assay (Fig. 3A). The hTERT negative 1-3 cells were used as a
control where negligible TRAP activity was recorded.
A number of studies have highlighted the comparatively high
expression levels of RuvBl2 in cancer specimens that may be of
clinical signiﬁcance. Elevated RuvBl2 expression has been reported
in hepatocellular carcinoma, malignant melanoma and bladder
cancer [44–46]. Expression levels of RuvBl2 protein in human co-
lon cancer tissue however have not been reported. In this study
we looked at RuvBl2 and hTERT expression in a cohort of colon
cancer patients (n = 170). Both RuvBl2 and hTERT were found to
localise to the nucleus of the tumour cells (Fig. 3B). Though previ-
ous studies have reported an association between hTERT expres-
sion levels and disease progression in colorectal cancer [47–49],
these studies primarily looked at hTERT transcript levels. Here,
78% of colon tumours expressed hTERT protein, 8% of which had
nuclear hTERT expression, similar levels of hTERT expression in
colorectal tumours have been previously reported [50]. No associ-
ation was observed between hTERT expression and any of the clas-
sic clinicopathological parameters, including, nodal status, Dukes
stage or disease recurrence (P = 0.101, 0.151 and 0.498 respec-
tively), however nuclear hTERT was found to signiﬁcantly associate
with advanced nodal disease (P = 0.04) (Table 2). 60% of colon can-
cers were found to be positive for RuvBl2, with 19% expressing nu-
clear RuvBl2. A signiﬁcant association between nuclear RuvBl2 and
nuclear hTERT expression was observed (P < 0.01). Furthermore, ina similar manner to hTERT, nuclear expression of RuvBl2 associ-
ated with advanced nodal disease of the colon (P = 0.05). A signif-
icant association between expression levels of pEts2 and nuclear
RuvBl2 was also observed (P = 0.05). These data ﬁrmly implicate
RuvBl2 and Ets2 in the regulation of hTERT in colon cancer which
has functional and clinical consequences.
Using proteomic discovery tools we identiﬁed RuvBl2 as a po-
tential regulator of hTERT. Molecular studies conﬁrmed a role for
RuvBl2 in the growth factor mediated transcriptional regulation
of hTERT and suggest that this may occur at least in part through
cooperation with Ets2. This is the ﬁrst report of RuvBl2 in tumour
tissue of colon cancer patients. Strong associations between RuvBl2
and hTERT in colon cancer reported here suggest that this is a
Table 2
Association of markers nuclear RuvBl2 and nuclear hTERT in colon cancer patient
TMA with clinicopathologic variables and pEts2 using Fisher’s exact test.
Patient population RuvBl2 +ve hTERT +ve
n = 170 n = 32 n = 13
% % P % P
Dukes’
A 9 19 0
B 43 13 5
C 48 25 0.16 11 0.28
T stage
1 1 0 0
2 14 17 0
3 74 18 10
4 11 26 0.81 5 0.36
Nodal status
0 52 14 4
1 26 18 7
2 22 32 0.06 16 0.10
Advance node
+ve 22 32 16
ve 78 15 0.03 5 0.04
Recurrence
+ve 23 18 10
ve 77 19 1.00 7 0.50
pEts2
+ve 16 36 4
ve 84 16 0.05 9 0.69
hTERT
+ve 8 54
ve 92 16 <0.01
Note: Positive expression of variables (top row) is expressed as a percentage of
patients in individual clinical classiﬁcations (ﬁrst column).
P. Flavin et al. / FEBS Letters 585 (2011) 2537–2544 2543functional relationship which could have signiﬁcant clinical
implications.
Acknowledgements
We thank Professor Roger Reddel, University of New South
Wales, Australia, for the 6G and 1-3C cells. This work was sup-
ported by Science Foundation Ireland, Breast Cancer Ireland and
the RSCI Research Committee.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2011.07.005.
References
[1] Blasco, M.A. (2007) Telomere length, stem cells and aging. Nat. Chem. Biol. 3,
640–649.
[2] Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100, 57–
70.
[3] Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D., Ho, P.L.,
Coviello, G.M., Wright, W.E., Weinrich, S.L. and Shay, J.W. (1994) Speciﬁc
association of human telomerase activity with immortal cells and cancer.
Science 266, 2011–2015.
[4] Shay, J.W. and Wright, W.E. (1989) Quantitation of the frequency of
immortalization of normal human diploid ﬁbroblasts by SV40 large T-
antigen. Exp. Cell Res. 184, 109–118.
[5] Cohen, S.B., Graham, M.E., Lovrecz, G.O., Bache, N., Robinson, P.J. and Reddel,
R.R. (2007) Protein composition of catalytically active human telomerase from
immortal cells. Science 315, 1850–1853.
[6] Fu, D. and Collins, K. (2007) Puriﬁcation of human telomerase complexes
identiﬁes factors involved in telomerase biogenesis and telomere length
regulation. Mol. Cell 28, 773–785.
[7] Smogorzewska, A. and de Lange, T. (2004) Regulation of telomerase by
telomeric proteins. Annu. Rev. Biochem. 73, 177–208.
[8] Atkinson, S.P., Hoare, S.F., Glasspool, R.M. and Keith, W.N. (2005) Lack of
telomerase gene expression in alternative lengthening of telomere cells is
associated with chromatin remodeling of the hTR and hTERT gene promoters.
Cancer Res. 65, 7585–7590.[9] Wang, S., Yuan, Y., Liao, L., Kuang, S.Q., Tien, J.C., O’Malley, B.W. and Xu, J.
(2009) Disruption of the SRC-1 gene in mice suppresses breast cancer
metastasis without affecting primary tumor formation. Proc. Natl. Acad. Sci.
USA 106, 151–156.
[10] Zinn, R.L., Pruitt, K., Eguchi, S., Baylin, S.B. and Herman, J.G. (2007) HTERT is
expressed in cancer cell lines despite promoter DNA methylation by
preservation of unmethylated DNA and active chromatin around the
transcription start site. Cancer Res. 67, 194–201.
[11] Kanaya, T., Kyo, S., Hamada, K., Takakura, M., Kitagawa, Y., Harada, H. and
Inoue, M. (2000) Adenoviral expression of p53 represses telomerase activity
through down-regulation of human telomerase reverse transcriptase
transcription. Clin. Cancer Res. 6, 1239–1247.
[12] Shats, I., Milyavsky, M., Tang, X., Stambolsky, P., Erez, N., Brosh, R., Kogan, I.,
Braunstein, I., Tzukerman, M., Ginsberg, D. and Rotter, V. (2004) P53-
dependent down-regulation of telomerase is mediated by p21waf1. J. Biol.
Chem. 279, 50976–50985.
[13] Xiong, J., Fan, S., Meng, Q., Schramm, L., Wang, C., Bouzahza, B., Zhou, J.,
Zafonte, B., Goldberg, I.D., Haddad, B.R., Pestell, R.G. and Rosen, E.M. (2003)
BRCA1 inhibition of telomerase activity in cultured cells. Mol. Cell Biol. 23,
8668–8690.
[14] Xu, D., Wang, Q., Gruber, A., Bjorkholm, M., Chen, Z., Zaid, A., Selivanova, G.,
Peterson, C., Wiman, K.G. and Pisa, P. (2000) Downregulation of telomerase
reverse transcriptase mRNA expression by wild type p53 in human tumor
cells. Oncogene 19, 5123–5133.
[15] Zhou, C. and Liu, J. (2003) Inhibition of human telomerase reverse
transcriptase gene expression by BRCA1 in human ovarian cancer cells.
Biochem. Biophys. Res. Commun. 303, 130–136.
[16] Deng, W.G., Jayachandran, G., Wu, G., Xu, K., Roth, J.A. and Ji, L. (2007) Tumor-
speciﬁc activation of human telomerase reverses transcriptase promoter
activity by activating enhancer-binding protein-2beta in human lung cancer
cells. J. Biol. Chem. 282, 26460–26470.
[17] Greenberg, R.A., O’Hagan, R.C., Deng, H., Xiao, Q., Hann, S.R., Adams, R.R.,
Lichtsteiner, S., Chin, L., Morin, G.B. and DePinho, R.A. (1999) Telomerase
reverse transcriptase gene is a direct target of c-Myc but is not functionally
equivalent in cellular transformation. Oncogene 18, 1219–1226.
[18] Kang, X., Chen, W., Kim, R.H., Kang, M.K. and Park, N.H. (2009) Regulation of
the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in
human oral squamous cell carcinoma cells. Oncogene 28, 565–574.
[19] Kyo, S., Takakura, M., Taira, T., Kanaya, T., Itoh, H., Yutsudo, M., Ariga, H. and
Inoue, M. (2000) Sp1 cooperates with c-Myc to activate transcription of the
human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 28,
669–677.
[20] Maida, Y., Kyo, S., Kanaya, T., Wang, Z., Yatabe, N., Tanaka, M., Nakamura, M.,
Ohmichi, M., Gotoh, N., Murakami, S. and Inoue, M. (2002) Direct activation of
telomerase by EGF through Ets-mediated transactivation of TERT via MAP
kinase signaling pathway. Oncogene 21, 4071–4079.
[21] Wu, K.J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J.
and Dalla-Favera, R. (1999) Direct activation of TERT transcription by c-MYC.
Nat. Genet. 21, 220–224.
[22] Xu, D., Dwyer, J., Li, H., Duan, W. and Liu, J.P. (2008) Ets2 maintains hTERT gene
expression and breast cancer cell proliferation by interacting with c-Myc. J.
Biol. Chem. 283, 23567–23580.
[23] Bazarov, A.V., Hines, W.C., Mukhopadhyay, R., Beliveau, A., Melodyev, S.,
Zaslavsky, Y. and Yaswen, P. (2009) Telomerase activation by c-Myc in human
mammary epithelial cells requires additional genomic changes. Cell Cycle 8,
3373–3378.
[24] Lebel, R., McDuff, F.O., Lavigne, P. and Grandbois, M. (2007) Direct
visualization of the binding of c-Myc/Max heterodimeric b-HLH-LZ to E-box
sequences on the hTERT promoter. Biochemistry 46, 10279–10286.
[25] Galang, C.K., Garcia-Ramirez, J., Solski, P.A., Westwick, J.K., Der, C.J., Neznanov,
N.N., Oshima, R.G. and Hauser, C.A. (1996) Oncogenic Neu/ErbB-2 increases
ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets
activation blocks Neu-mediated cellular transformation. J. Biol. Chem. 271,
7992–7998.
[26] Myers, E., Hill, A.D., Kelly, G., McDermott, E.W., O’Higgins, N.J., Buggy, Y. and
Young, L.S. (2005) Associations and interactions between Ets-1 and Ets-2 and
coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin. Cancer
Res. 11, 2111–2122.
[27] Foulds, C.E., Nelson, M.L., Blaszczak, A.G. and Graves, B.J. (2004) Ras/mitogen-
activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300
recruitment. Mol. Cell Biol. 24, 10954–10964.
[28] Seth, A. and Watson, D.K. (2005) ETS transcription factors and their emerging
roles in human cancer. Eur. J. Cancer 41, 2462–2478.
[29] Ito, Y., Takeda, T., Okada, M. and Matsuura, N. (2002) Expression of ets-1 and
ets-2 in colonic neoplasms. Anticancer Res. 22, 1581–1584.
[30] Ong, S.E., Blagoev, B., Kratchmarova, I., Kristensen, D.B., Steen, H., Pandey, A.
and Mann, M. (2002) Stable isotope labeling by amino acids in cell culture,
SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell
Proteomics 1, 376–386.
[31] Venteicher, A.S., Meng, Z., Mason, P.J., Veenstra, T.D. and Artandi, S.E. (2008)
Identiﬁcation of ATPases pontin and reptin as telomerase components
essential for holoenzyme assembly. Cell 132, 945–957.
[32] Li, W., Zeng, J., Li, Q., Zhao, L., Liu, T., Bjorkholm, M., Jia, J. and Xu, D. (2010)
Reptin is required for the transcription of telomerase reverse transcriptase and
over-expressed in gastric cancer. Mol. Cancer 9, 132.
2544 P. Flavin et al. / FEBS Letters 585 (2011) 2537–2544[33] Al-azawi, D., Ilroy, M.M., Kelly, G., Redmond, A.M., Bane, F.T., Cocchiglia, S.,
Hill, A.D. and Young, L.S. (2008) Ets-2 and p160 proteins collaborate to
regulate c-Myc in endocrine resistant breast cancer. Oncogene 27, 3021–3031.
[34] Yang, B.S., Hauser, C.A., Henkel, G., Colman, M.S., Van Beveren, C., Stacey, K.J.,
Hume, D.A., Maki, R.A. and Ostrowski, M.C. (1996) Ras-mediated
phosphorylation of a conserved threonine residue enhances the
transactivation activities of c-Ets1 and c-Ets2. Mol. Cell Biol. 16, 538–547.
[35] McIlroy, M., McCartan, D., Early, S., Pennington, S., Hill, A.D. and Young, L.S.
(2010) Interaction of developmental transcription factor HOXC11 with steroid
receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast
cancer [corrected]. Cancer Res. 70, 1585–1594.
[36] Cong, Y.S., Wen, J. and Bacchetti, S. (1999) The human telomerase catalytic
subunit hTERT: organization of the gene and characterization of the promoter.
Hum. Mol. Genet. 8, 137–142.
[37] Harvey, J.M., Clark, G.M., Osborne, C.K. and Allred, D.C. (1999) Estrogen
receptor status by immunohistochemistry is superior to the ligand-binding
assay for predicting response to adjuvant endocrine therapy in breast cancer. J.
Clin. Oncol. 17, 1474–1481.
[38] Yuan, J., Yang, B.M., Zhong, Z.H., Shats, I., Milyavsky, M., Rotter, V., Lock, R.B.,
Reddel, R.R. and MacKenzie, K.L. (2009) Upregulation of survivin during
immortalization of nontransformed human ﬁbroblasts transduced with
telomerase reverse transcriptase. Oncogene 28, 2678–2689.
[39] Bryan, T.M., Englezou, A., Gupta, J., Bacchetti, S. and Reddel, R.R. (1995)
Telomere elongation in immortal human cells without detectable telomerase
activity. EMBO J. 14, 4240–4248.
[40] Cesare, A.J. and Reddel, R.R. (2008) Telomere uncapping and alternative
lengthening of telomeres. Mech. Ageing Dev. 129, 99–108.
[41] Jha, S. and Dutta, A. (2009) RVB1/RVB2: running rings around molecular
biology. Mol. Cell 34, 521–533.
[42] Goueli, B.S. and Janknecht, R. (2003) Regulation of telomerase reverse
transcriptase gene activity by upstream stimulatory factor. Oncogene 22,
8042–8047.[43] Wood, M.A., McMahon, S.B. and Cole, M.D. (2000) An ATPase/helicase complex
is an essential cofactor for oncogenic transformation by c-Myc. Mol. Cell 5,
321–330.
[44] Rousseau, B., Menard, L., Haurie, V., Taras, D., Blanc, J.F., Moreau-Gaudry, F.,
Metzler, P., Hugues, M., Boyault, S., Lemiere, S., Canron, X., Costet, P., Cole, M.,
Balabaud, C., Bioulac-Sage, P., Zucman-Rossi, J. and Rosenbaum, J. (2007)
Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2
in human hepatocellular carcinoma. Hepatology 46, 1108–1118.
[45] Talantov, D., Mazumder, A., Yu, J.X., Briggs, T., Jiang, Y., Backus, J., Atkins, D. and
Wang, Y. (2005) Novel genes associated with malignant melanoma but not
benign melanocytic lesions. Clin. Cancer Res. 11, 7234–7242.
[46] Sanchez-Carbayo, M., Socci, N.D., Lozano, J., Saint, F. and Cordon-Cardo, C.
(2006) Deﬁning molecular proﬁles of poor outcome in patients with invasive
bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24, 778–789.
[47] Terrin, L., Rampazzo, E., Pucciarelli, S., Agostini, M., Bertorelle, R., Esposito, G.,
DelBianco, P., Nitti, D. and De Rossi, A. (2008) Relationship between tumor and
plasma levels of hTERT mRNA in patients with colorectal cancer: implications
for monitoring of neoplastic disease. Clin. Cancer Res. 14, 7444–7451.
[48] Gertler, R., Rosenberg, R., Stricker, D., Friederichs, J., Hoos, A., Werner, M., Ulm,
K., Holzmann, B., Nekarda, H. and Siewert, J.R. (2004) Telomere length and
human telomerase reverse transcriptase expression as markers for
progression and prognosis of colorectal carcinoma. J. Clin. Oncol. 22, 1807–
1814.
[49] Naito, Y., Takagi, T., Handa, O., Ishikawa, T., Matsumoto, N., Yoshida, N., Kato,
H., Ando, T., Takemura, T., Itani, K., Hisatomi, H., Tsuchihashi, Y. and
Yoshikawa, T. (2001) Telomerase activity and expression of telomerase RNA
component and catalytic subunits in precancerous and cancerous colorectal
lesions. Tumour Biol. 22, 374–382.
[50] Lam, A.K., Ong, K. and Ho, Y.H. (2008) HTERT expression in colorectal
adenocarcinoma: correlations with p21, p53 expressions and
clinicopathological features. Int. J. Colorectal Dis. 23, 587–594.
